Curocell Inc.
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
372320 | KO
Overview
Corporate Details
- ISIN(s):
- KR7372320002
- LEI:
- Country:
- South Korea
- Address:
- 대전광역시 유성구 국제과학16로 11, 대전광역시
- Website:
- https://curocellbtx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Curocell Inc. is a clinical-stage biotechnology company specializing in the research and development of Chimeric Antigen Receptor T-cell (CAR-T) therapies for cancer. A pioneer in South Korea, the company developed Limkato, the nation's first CAR-T therapy to complete clinical trials and be submitted for regulatory approval. Curocell's key innovation is its proprietary OVIS™ platform technology, which is engineered to enhance the efficacy and persistence of CAR-T cells by overcoming immune checkpoint-induced exhaustion. The company aims to address the limitations of existing immunotherapies and provide new treatment options for cancer patients, supported by its state-of-the-art GMP manufacturing facility.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-17 00:00 |
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
|
Korean | 75.9 KB | ||
| 2025-08-28 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-08-13 00:00 |
Interim Report
반기보고서 (2025.06)
|
Korean | 1.6 MB | ||
| 2025-08-08 00:00 |
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인신청) (CRC01(안발캅타젠오토류셀, 안발셀)의 B세포 급성 림프모구성 성인…
|
Korean | 12.5 KB | ||
| 2025-08-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-08-04 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 101.7 KB | ||
| 2025-08-01 00:00 |
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (CD19 CAR-T 치료제 CRC01의 전신 홍반성 루푸스 제1,2…
|
Korean | 12.0 KB | ||
| 2025-07-23 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-07-21 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-07-09 00:00 |
Regulatory News Service
자산재평가결과(자율공시)
|
Korean | 9.4 KB | ||
| 2025-07-02 00:00 |
Regulatory News Service
자산재평가실시결정(자율공시)
|
Korean | 5.0 KB | ||
| 2025-06-30 00:00 |
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (CD19 CAR-T 치료제 CRC01의 전신 홍반성 루푸스 제1,2상 임…
|
Korean | 8.6 KB | ||
| 2025-05-14 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.5 MB | ||
| 2025-04-14 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-04-14 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB |
Automate Your Workflow. Get a real-time feed of all Curocell Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Curocell Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Curocell Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
